Funding
← Back to your selection

Alpha Wave

Activity from announced rounds

Activity in this selectionUnited States · Oct 14, 2026 · Jul 17, 2026
Rounds participated in
1
Confirmed lead rounds
1
All roles disclosed
New companies
1
First participation on record · 0 follow-on
Funding in participating rounds
$70M
1 disclosed · full round size, not this investor’s share

By stage

Series B1

By primary sector

Biotech1

By country

United States1

Rounds

1 in this selection
Moonwalk Biosciences

Moonwalk Biosciences is developing adipose-targeted siRNA medicines for obesity and cardiometabolic disease. Its lead programs are designed to alter fat-tissue pathways while limiting effects on other tissues, with the lead obesity candidate in IND-enabling development ahead of planned human testing in 2027.

$70MSeries B
Lead